Busulfan intravenous - Otsuka Pharmaceutical

Drug Profile

Busulfan intravenous - Otsuka Pharmaceutical

Alternative Names: Busilvex; Busulfan injection - Orphan Medical; Busulfex; IV busulfan - Otsuka; KRN 246

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orphan Medical; PDL BioPharma
  • Developer Kirin Holdings Company; Orphan Medical; Otsuka Pharmaceutical; Tzamal Pharma
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haematological malignancies
  • Phase II T cell lymphoma

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in T-cell lymphoma (Combination therapy, Second-line therapy or greater, In volunteers) in South Korea (IV) (NCT02859402)
  • 25 Jul 2016 Busulfan intravenous licensed to Grupo Biotoscana in Colombia, Chile, Ecuador and Peru
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top